Company news
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) news
Oric Pharmaceuticals, Inc. news releases on 6ix. Latest, Oct 7, 2021: ORIC Pharmaceuticals Presents Initial Clinical Data from Phase 1b Trial of ORIC-101…
Press releases — page 3
ORIC Pharmaceuticals Presents Initial Clinical Data from Phase 1b Trial of ORIC-101 in Combination with Enzalutamide and Preclinical Data on ORIC-114 at AACR-NCI-EORTC
October 6, 2021
ORIC Pharmaceuticals Announces Multiple Data Presentations at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
September 29, 2021
ORIC Pharmaceuticals Announces Update on ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor
September 20, 2021
ORIC Pharmaceuticals Appoints Steven L. Hoerter to its Board of Directors
August 15, 2021
ORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update
August 9, 2021
ORIC Pharmaceuticals Announces FDA Clearance of IND Application for ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor
June 27, 2021
ORIC Pharmaceuticals Reports Initial Clinical Data Being Presented at ASCO from Phase 1b Trial of ORIC-101 in Combination with Nab-Paclitaxel
June 1, 2021
ORIC Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
May 25, 2021
ORIC Pharmaceuticals to Host Conference Call with KOL to Review Initial Data Being Presented at ASCO from Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel
May 24, 2021
ORIC Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update
May 5, 2021
ORIC Pharmaceuticals to Present Initial Data from Ongoing Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel at the 2021 ASCO Annual Meeting
April 27, 2021
ORIC Pharmaceuticals Presents Posters on Four Programs at the 2021 American Association for Cancer Research (AACR) Annual Meeting
April 11, 2021
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update
March 22, 2021
ORIC Pharmaceuticals to Present Posters on Four Programs at the 2021 American Association for Cancer Research (AACR) Annual Meeting
March 9, 2021
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Milestones
January 10, 2021
ORIC Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 3, 2021
ORIC Pharmaceuticals Announces Initiation of Expansion Cohorts in Phase 1b Study of ORIC-101
December 20, 2020
ORIC Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
November 16, 2020
ORIC Pharmaceuticals Announces Pricing of Upsized Public Offering
November 12, 2020
ORIC Pharmaceuticals Announces Proposed Public Offering of Common Stock
November 9, 2020
ORIC Pharmaceuticals Reports Third Quarter 2020 Financial and Operational Update
November 4, 2020
ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program
October 18, 2020
ORIC Pharmaceuticals Announces Presentation of Preclinical Data on Glucocorticoid Receptor Antagonist Overcoming Resistance to an Androgen Receptor Degrader at the 32nd EORTC-NCI-AACR Symposium 2020
October 8, 2020
ORIC Pharmaceuticals Reports Second Quarter 2020 Financial and Operational Update
August 4, 2020
ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive Worldwide License to Highly Selective Allosteric PRC2 Inhibitors from Mirati Therapeutics
August 4, 2020
ORIC Pharmaceuticals to Host Second Quarter 2020 Financial Results Conference Call
August 2, 2020
ORIC Pharmaceuticals Presents Preclinical Data on Glucocorticoid Receptor Antagonist and CD73 Inhibitor Programs at the 2020 American Association for Cancer Research Virtual Annual Meeting II
June 21, 2020
ORIC Pharmaceuticals Appoints Lori Kunkel, M.D., to its Board of Directors
June 8, 2020
ORIC Pharmaceuticals Announces Five Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting II
May 26, 2020
ORIC Pharmaceuticals to Present at the Jefferies 2020 Global Healthcare Conference
May 25, 2020
ORIC Pharmaceuticals Reports First Quarter 2020 Financial and Operational Results
May 19, 2020
ORIC Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 27, 2020
ORIC Pharmaceuticals Presents Preclinical Data on CD73 Inhibitor at the American Association for Cancer Research (AACR) Virtual Annual Meeting
April 26, 2020